Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Infants' Responses to Live, Attenuated, B Level, Jeryl Lynn Mumps Vaccine

Infants' Responses to Live, Attenuated, B Level, Jeryl Lynn Mumps Vaccine Abstract A study was designed to better characterize the serological responses of infants in the second year of life to live, attenuated, B level, Jeryl Lynn mumps-virus vaccine given singly since previous studies with small numbers had implied poorer seroconversion ratios in this age group. Of the 88 infants 12 to 24 months of age, 17 (or 19%) were shown to have had prior infection with the mumps virus. Seroconversion rates in the 71 infants who were initially seronegative were comparable to those reported in other children and adults. The study clearly confirms the feasibility of administering the mumps-virus vaccine either singly or in combination to infants greater than or equal to 12 months of age. References 1. Weibel RE, Stokes J Jr, Buynak EB, et al: Live attenuated mumps-virus vaccine: III. Clinical and serologic aspects in a field evaluation . New Eng J Med 276:245-251, 1967.Crossref 2. Horowitz SD, Nagatani MS, Bowen GS, et al: The acquisition of delayed hypersensitivity following attenuated mumps virus infection . Pediatrics 45:77-82, 1970. 3. Davidson WL, Buynak EB, Leagus MB, et al: Vaccination of adults with live attenuated mumps virus vaccine . JAMA 201:995-998, 1967.Crossref 4. Buynak EB, Whitman JE Jr, Roehm RR, et al: Comparison of neutralization and hemagglutination-inhibition techniques for measuring mumps antibody . Proc Soc Exp Biol Med 125:1068-1071, 1967.Crossref 5. Rosen L: Hemagglutination by adenoviruses . Virology 5:574-577, 1958.Crossref 6. Eckert HL, Portnoy B, Salvatore MA, et al: The hemagglutination inhibition and complement fixation tests in the serodiagnosis of mumps central nervous system disease . Amer J Clin Path 47:481-483, 1967. 7. Weibel RE, Buynak EB, Whitman JE Jr, et al: Jeryl Lynn strain live mumps-virus vaccine: Durable immunity for three years following vaccination . JAMA 207:1667-1670, 1969.Crossref 8. Hilleman MR, Weibel RE, Buynak EB, et al: Live attenuated mumps-virus vaccine: IV. Protective efficacy as measured in a field evaluation . New Eng J Med 276:252-258, 1967.Crossref 9. Karchmer AW, Friedman JP, Casey HL, et al: Simultaneous administration of live virus vaccines: Measles, mumps, poliomyelitis, and smallpox . Amer J Dis Child 121:382-388, 1971.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Diseases of Children American Medical Association

Infants' Responses to Live, Attenuated, B Level, Jeryl Lynn Mumps Vaccine

Loading next page...
 
/lp/american-medical-association/infants-responses-to-live-attenuated-b-level-jeryl-lynn-mumps-vaccine-hjPN1ExU4Y
Publisher
American Medical Association
Copyright
Copyright © 1972 American Medical Association. All Rights Reserved.
ISSN
0002-922X
DOI
10.1001/archpedi.1972.02110130068010
Publisher site
See Article on Publisher Site

Abstract

Abstract A study was designed to better characterize the serological responses of infants in the second year of life to live, attenuated, B level, Jeryl Lynn mumps-virus vaccine given singly since previous studies with small numbers had implied poorer seroconversion ratios in this age group. Of the 88 infants 12 to 24 months of age, 17 (or 19%) were shown to have had prior infection with the mumps virus. Seroconversion rates in the 71 infants who were initially seronegative were comparable to those reported in other children and adults. The study clearly confirms the feasibility of administering the mumps-virus vaccine either singly or in combination to infants greater than or equal to 12 months of age. References 1. Weibel RE, Stokes J Jr, Buynak EB, et al: Live attenuated mumps-virus vaccine: III. Clinical and serologic aspects in a field evaluation . New Eng J Med 276:245-251, 1967.Crossref 2. Horowitz SD, Nagatani MS, Bowen GS, et al: The acquisition of delayed hypersensitivity following attenuated mumps virus infection . Pediatrics 45:77-82, 1970. 3. Davidson WL, Buynak EB, Leagus MB, et al: Vaccination of adults with live attenuated mumps virus vaccine . JAMA 201:995-998, 1967.Crossref 4. Buynak EB, Whitman JE Jr, Roehm RR, et al: Comparison of neutralization and hemagglutination-inhibition techniques for measuring mumps antibody . Proc Soc Exp Biol Med 125:1068-1071, 1967.Crossref 5. Rosen L: Hemagglutination by adenoviruses . Virology 5:574-577, 1958.Crossref 6. Eckert HL, Portnoy B, Salvatore MA, et al: The hemagglutination inhibition and complement fixation tests in the serodiagnosis of mumps central nervous system disease . Amer J Clin Path 47:481-483, 1967. 7. Weibel RE, Buynak EB, Whitman JE Jr, et al: Jeryl Lynn strain live mumps-virus vaccine: Durable immunity for three years following vaccination . JAMA 207:1667-1670, 1969.Crossref 8. Hilleman MR, Weibel RE, Buynak EB, et al: Live attenuated mumps-virus vaccine: IV. Protective efficacy as measured in a field evaluation . New Eng J Med 276:252-258, 1967.Crossref 9. Karchmer AW, Friedman JP, Casey HL, et al: Simultaneous administration of live virus vaccines: Measles, mumps, poliomyelitis, and smallpox . Amer J Dis Child 121:382-388, 1971.Crossref

Journal

American Journal of Diseases of ChildrenAmerican Medical Association

Published: Jul 1, 1972

References